Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats (Journal of Psychopharmacology 21, 2, DOI: 10.1177/0269881107067076);Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats

Journal of Psychopharmacology

Volumn 21, Issue 2, 2007, Pages 179-190

  Goudie, Andrew J ^a   Cooper, Gillian D ^a   Cole, Jon C ^a   Sumnall, Harry R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Antipsychotic; Chlordiazepoxide; Clozapine; Cyproheptadine; Drug discrimination; Movement disorders; Rats; Weight gain; Withdrawal

Indexed keywords

CHLORDIAZEPOXIDE; CLOZAPINE; CYPROHEPTADINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; IN VIVO STUDY; LONG TERM CARE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 33847123666     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108096191     Document Type: Erratum

References (60)

1. Akhondzadeh S, Mohammadi M, Amini-Nooshabadi H, Davari-Ashtiani R (1999) Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J Clin Pharm Ther 24: 49 - 52
2. Arnt, J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63 - 101
3. Browne R, Koe B (1982) Clozapine and agents with similar behavioural and biochemical properties. In Colpaert F, Slangen J (eds). Drug Discrimination: Applications in CNS Pharmacology. Elsevier Biomedical Press, Amsterdam, pp. 241 - 256
4. Bruhwyler J, Liegeois J, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J, Geczy J (1997) JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res 36: 255 - 264
5. Bymaster F, Felder C, Tzavara E, Nomikos G, Calligaro D, Mckinzie D (2003) Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1125 - 1143
6. Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, Tye N, Seeman P, Wong D (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neurophychopharmacology 14: 87 - 96
7. Capuano B, Crosby I, Lloyd E (2002) Schizophrenia: genesis, receptorology and current therapeutics. Curr Med Chem 9: 521 - 548
8. Carey G, Bergman J (1997) Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology 132: 261 - 269
9. Chaudhry I, Soni S, Hellewell J, Deakin J (2002) Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia. Schizophr Res 53: 17 - 24
10. Comer S, Haney M, Fischman M, Foltin R (1997) Cyproheptadine produced modest increases in total caloric intake by humans. Physiol Behav 62: 831 - 839
11. Davies M, Compton-Toth B, Hufeisen S, Meltzer H, Roth B (2005) The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology 178: 451 - 460
12. Daviss W, Scott J (2004) A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol 14: 65 - 73
13. De Lucas Taracena M, Alcaina Prosper T, Huelamo Ortega M (2000) Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine. Actas Esp Psiquiatr 28: 270 - 272
14. Doat M, Rabin R, Winter J (2002) The effect of chronic treatment with clozapine and haloperidol on stimulus control by DOM. Int J Neuropsychopharmacol 5: 153 - 158
15. Fasciano J, Steele T, Castagnoli N, Katz J, Ricaurte G (1997) The effect of N-methylation on fenfluramine's neurotoxic and pharmacologic actions. Brain Res 763: 182 - 190
16. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A (2001) Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 21: 612 - 615
17. Goudie A (2000) What is the clinical significance of the discontinuation syndrome seen with clozapine? J Psychopharmacol 14: 188 - 192
18. Goudie A, Taylor A (1998) Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 135: 392 - 400
19. Goudie A, Smith J (1999) Discriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 64: 193 - 201
20. Goudie A, Smith J, Cole J (2004) Stimulus properties of the 'atypical' antipsychotic zotepine in rats: comparisons with clozapine and quetiapine. Pharmacol Biochem Behav 77: 163 - 173
21. Goudie A, Smith J, Millan M (2004) Characterization of the effects of receptor-selective ligands in rats discriminating the novel antipsychotic quetiapine. Psychopharmacology 171: 212 - 222
22. Goudie A, Smith J, Robertson A, Cavanagh C (1999) Clozapine as a drug of dependence. Psychopharmacology 142: 369 - 374
23. Goudie A, Smith J, Taylor A, Taylor M, Tricklebank M (1998) Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9: 699 - 710
24. Halmi K, Eckert E, Falk J (1982) Cyproheptadine for anorexia nervosa. Lancet 1: 1357 - 1358
25. Hartfield A, Moore N, Clifton P (2003) Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav 76: 251 - 258
26. Hartfield A, Moore N, Clifton P (2005) Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology (In Press)
27. Hutchison K, Wooden A, Swift R, Smolen A, McGeary J, Adler L, Paris L (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28: 1882 - 1888
28. Kapur S, Zipursky R (1998) Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and Serotonin2 receptor occupancy. Arch Gen Psychiatry 55: 666 - 667
29. Kapur S, Mizrahi, R, Li M (2005) From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 79: 59 - 68
30. Kelley B, Porter J (1997) The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57: 707 - 719
31. Ketelaars C, Bruinvels J (1989) The anti-conflict effect of cyproheptadine is not mediated by its 5-hydroxytryptamine antagonistic property. Life Sci 44: 1743 - 1749
32. Kuhar M, Joyce A (2003) Is the onset of psychoactive drug effects compatible with a protein-synthesis mechanism? Neuropsychopharmacology 28 (suppl. 1). S94 - S97
33. Kulikov A, Avgustinovich D, Kolpakov V, Maslova G, Popova N (1995) 5-HT2A serotonin receptors in the brain of rats and mice hereditarily predisposed to catalepsy. Pharmacol Biochem Behav 50: 383 - 387
34. Lee H, Song D, Kim J, Lee Y, Han E, Yoo K (1995) Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol 10: 67 - 72
35. Leucht S, Busch R, Hamann J, Kissling W, Kane J (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57: 1543 - 1549
36. Leysen J, Awouters F, Kennis L, Laduron P, Vandenberk J, Janssen P (1981) Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 28: 1015 - 1022
37. Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B, Severe J, Hsiao J (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353: 1209 - 1223
38. Marx C, Van Doren M, Duncan G, Lieberman J, Morrow A (2003) Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28: 1 - 13
39. Meltzer H (1998) In reply: do loxapine plus cyproheptadine make an atypical antipsychotic? Arch Gen Psychiatry 55: 667 - 668
40. Meltzer H, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59: 19 - 27
41. Meltzer H, Lee M, Ranjan R, Mason E, Cola P (1996) Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology 124: 176 - 187
42. Millan M, Schreiber R, Monneyron S, Denorme B, Melon C, Queriaux S, Dekeyne A (1999) S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 289: 427 - 436
43. Millan M, Brocco M, Rivet J, Audinot V, Newman-Tancredi A, Maiofiss L, Queriaux S, Despaux N, Peglion J, Dekeyne A (2000) S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one). a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)-and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292: 54 - 66
44. Moore N, Tye N, Axton M, Risius F (1992) The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262: 545 - 551
45. Natesan S, Vanderspek S, Nobrega J, McClelland R, Kapur S (2005) Contrasting loxapine to its isomer isoloxapine - the critical role of in vivo D2 blockade in determining atypicality. Schizophr Res 77: 189 - 199
46. Porter J, Prus A, Vann R, Varvel S (2005) Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats. Psychopharmacology 178: 67 - 77
47. Poyurovsky M, Weizman A (2001) Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 179: 4 - 8
48. Prus A, Baker L, Meltzer H (2004) Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77: 199 - 208
49. Roth B, Sheffler D, Kroeze W (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353 - 359
50. Seeman P (2005) An update of fast-off dopamine d2 atypical antipsychotics. Am J Psychiatry 162: 1984 - 1985
51. Shilliam C, Dawson L (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist. Neuropsychopharmacology 30: 372 - 380
52. Silver H, Blacker M, Weller M, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25: 502 - 504
53. Silver H, Blacker M, Weller M, Lerer B (1991) Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study. Biol Psychiatry 30: 523 - 525
54. Smith J, Goudie A (2002) Discriminative stimulus properties in rats of the novel antipsychotic quetiapine. Exp Clin Psychopharmacol 10: 376 - 384
55. Tandon R, Fleischhacker W (2005) Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79: 145 - 155
56. Tang A, Franklin S, Himes C, Smith M, Tenbrink R (1997) PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther 281: 440 - 447
57. Weiss D, Aizenberg D, Hermesh H, Zemishlany Z, Munitz H, Radwan M, Weizman A (1995) Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 167: 483 - 486
58. Young A (1991) Tolerance to drugs acting as discriminative stimuli. In: Glennon, R, Jarbe T, Frankenheim J (eds) Drug Discrimination: Applications to Drug Abuse Research. NIDA Research Monograph 116. National Institute of Drug Abuse, Rockville. 197 - 212
59. Young R, Khorana N, Bondareva T, Glennon R (2005) Pizotyline effectively attenuates the stimulus effects of N-Methyl-3,4-methylenedioxyamphetamine (MDMA). Pharmacol Biochem Behav 82: 404 - 410
60. Zesiewicz T, Borra S, Hauser R (2002) Clozapine withdrawal symptoms in a Parkinson's disease patient. Mov Disord 17: 1365 - 1367